文献速递儿童青少年精神

脐血对乙酰氨基酚暴露生物标志物与儿童ADHD及ASD风险的关联

Association of Cord Plasma Biomarkers of In Utero Acetaminophen Exposure With Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Childhood.
PubMed 文献 · JAMA Psychiatry · 2020-01-01

该前瞻性队列研究分析996对母婴,检测出生时脐血血浆中对乙酰氨基酚三种代谢物,发现脐血对乙酰氨基酚负荷第二、三分位与儿童ADHD和ASD诊断风险增高相关,呈剂量-反应关系。

要点

  • 脐血中对乙酰氨基酚负荷较高与儿童ADHD风险增加相关。
  • 脐血中对乙酰氨基酚负荷较高与儿童ASD风险增加相关。
  • 关联在多个敏感性分析和亚组分析中保持一致。

核心结论

  • 脐血中对乙酰氨基酚的胎儿暴露生物标志物与儿童ADHD和ASD风险显著增加相关,呈剂量-反应关系。

主要发现

  • 996名参与者平均(SD)年龄9.8(3.9)岁,548名(55.0%)为男性。
  • 最终样本包括257名(25.8%)仅ADHD、66名(6.6%)仅ASD、42名(4.2%)同时有ADHD和ASD、304名(30.5%)其他发育障碍、327名(32.8%)神经发育正常。
  • 所有脐血血浆样本均可检测到未改变的对乙酰氨基酚。
  • 与第一三分位相比,脐血对乙酰氨基酚负荷第二、第三三分位与ADHD诊断风险增高相关(第二三分位OR 2.26,95%CI 1.40-3.69;第三三分位OR 2.86,95%CI 1.77-4.67)。
  • 与第一三分位相比,脐血对乙酰氨基酚负荷第二、第三三分位与ASD诊断风险增高相关(第二三分位OR 2.14,95%CI 0.93-5.13;第三三分位OR 3.62,95%CI 1.62-8.60)。

关键数值与推荐

  • 敏感性分析和亚组分析在潜在混杂因素(包括母亲适应证、物质使用、早产、儿童年龄和性别)各层中均发现对乙酰氨基酚负荷与ADHD和ASD的关联一致,ADHD的OR点估计范围为2.3至3.5,ASD为1.6至4.1。

临床怎么用

  • 该研究提示产前对乙酰氨基酚暴露可能与儿童ADHD和ASD风险相关,需进一步研究以明确因果关联和临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prior studies have raised concern about maternal acetaminophen use during pregnancy and increased risk of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in their children; however, most studies have relied on maternal self-report. OBJECTIVE: To examine the prospective associations between cord plasma acetaminophen metabolites and physician-diagnosed ADHD, ASD, both ADHD and ASD, and developmental disabilities (DDs) in childhood. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study analyzed 996 mother-infant dyads, a subset of the Boston Birth Cohort, who were enrolled at birth and followed up prospectively at the Boston Medical Center from October 1, 1998, to June 30, 2018. EXPOSURES: Three cord acetaminophen metabolites (unchanged acetaminophen, acetaminophen glucuronide, and 3-[N-acetyl-l-cystein-S-yl]-acetaminophen) were measured in archived cord plasma samples collected at birth. MAIN OUTCOMES AND MEASURES: Physician-diagnosed ADHD, ASD, and other DDs as documented in the child's medical records. RESULTS: Of 996 participants (mean [SD] age, 9.8 [3.9] years; 548 [55.0%] male), the final sample included 257 children (25.8%) with ADHD only, 66 (6.6%) with ASD only, 42 (4.2%) with both ADHD and ASD, 304 (30.5%) with other DDs, and 327 (32.8%) who were neurotypical. Unchanged acetaminophen levels were detectable in all cord plasma samples. Compared with being in the first tertile, being in the second and third tertiles of cord acetaminophen burden was associated with higher odds of ADHD diagnosis (odds ratio [OR] for second tertile, 2.26; 95% CI, 1.40-3.69; OR for third tertile, 2.86; 95% CI, 1.77-4.67) and ASD diagnosis (OR for second tertile, 2.14; 95% CI, 0.93-5.13; OR for third tertile, 3.62; 95% CI, 1.62-8.60). Sensitivity analyses and subgroup analyses found consistent associations between acetaminophen buden and ADHD and acetaminophen burden and ASD across strata of potential confounders, including maternal indication, substance use, preterm birth, and child age and sex, for which point estimates for the ORs vary from 2.3 to 3.5 for ADHD and 1.6 to 4.1 for ASD. CONCLUSIONS AND RELEVANCE: Cord biomarkers of fetal exposure to acetaminophen were associated with significantly increased risk of childhood ADHD and ASD in a dose-response fashion. Our findings support previous studies regarding the association between prenatal and perinatal acetaminophen exposure and childhood neurodevelopmental risk and warrant additional investigations.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Ji Y, Azuine RE, Zhang Y, et al. Association of Cord Plasma Biomarkers of In Utero Acetaminophen Exposure With Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Childhood. JAMA Psychiatry. 2020. PMID: 31664451. doi:10.1001/jamapsychiatry.2019.3259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。